Home > Investors relations> News & events > Press releases Press releases Risk Disclosure These press releases are provided for your convenience only and are not necessarily updated. They may contain forward-looking information which is subject to risks and uncertainties that could cause the actual results to differ materially. Factors that may affect future operations and business of the company are described in the prospectus relating to the company’s public offering or in the company’s annual report. 2010 2009 2008 2007 2006 2005 2004-1998 09 November 2004  3rd quarter 2004: Sales revenues and operating result 05 October 2004  Half year 2004 consolidated results 05 August 2004  Half year 2004 consolidated sales revenues Sustained growth with increasing operating profit 09 July 2004  Acquisition of MEL confirmed - Sales revenues for the second quarter increase by more than 75% 25 May 2004  Cerep increases resources in drug discovery and expands competencies in cancer 11 May 2004  First quarter 2004 consolidated sales revenues increased - Positive operating results 26 March 2004  2003 consolidated results 01 March 2004  Cerep confirms net profitability for 2003 12 February 2004  Lilly renews and expands the major profiling agreement signed with Cerep for 2004 12 February 2004  2003 fourth quarter results - Sales revenue and operating result 15 January 2004  Cerep to acquire Clinical Development Service Organization Hesperion 13 November 2003  2003 third quarter sales and operating result - Service activities grow 30% at constant exchange rates - 01 October 2003  Cerep reports consolidated results for first half 2003 16 September 2003  Cerep announces IND Filing for a drug candidate developed with Bristol-Myers Squibb 07 August 2003  Cerep reports consolidated sales for the second quarter 2003 Service revenue increased by 9% 23 June 2003  Cerep revises its guidance for 2003 12 May 2003  Consolidated sales for first quarter of 2003 - Service activity growth in a difficult economic 26 March 2003  2002 consolidated results Continued sustained growth 18 February 2003  Cerep enters into a significant profiling and BioPrint® database agreement with Lilly 13 February 2003  Consolidated results for 2002 - Cerep confirms its growth 10 February 2003  Cerep and Sanofi-Synthélabo renew their drug discovery collaboration for 2003 17 January 2003  Cerep enters strategic collaboration with Pfizer based on BioPrint® technology 05 December 2002  Cerep anticipates historic operating profit in 2002 13 November 2002  Cerep reports third quarter 2002 consolidated sales: 18% growth in revenue and increased profitability 02 October 2002  Roche gains access to Cerep’s proprietary BioPrint™ database and technology 01 Octobre 2002  Cerep reports consolidated results for first half 2002 07 August 2002  Cerep reports consolidated sales for second quarter 2002 - 25% growth from Q2 2001 01 July 2002  Cerep and Sanofi-Synthélabo sign two research service agreements 14 May 2002  Cerep reports consolidated sales for first quarter 2002 23% growth from Q1 2001 03 May 2002  Cerep announces success in two research programs partnered with Bristol-Myers Squibb 25 March 2002  2001 consolidated results - Cerep confirms performance 14 February  2002  Cerep reports 2001 consolidated sales - 51% growth - 28 January  2002   Cerep and Sanofi-Synthélabo expand their drug discovery collaboration 12 November 2001  Cerep signs a scientific collaborative agreement with Aventis Pharma 07 November 2001  Cerep reports third quarter 2001 consolidated sales and confirms its sustained growth 29 Octobre 2001  Cerep announces a BioPrint™ based research and development agreement with Sepracor 02 October 2001   Cerep announces a capital increase of approximately Euros 11.7 million 25 September 2001  Cerep reports a strong increase in first half 2001 consolidated results Net profit for the period 02 August 2001  Cerep reports second quarter 2001 consolidated sales up 56% and posts an operating profit for the first half 13 June 2001  Cerep announces a drug discovery agreement with Aventis 25 April 2001  Cerep announces first quarter consolidated sales: up 57% Positive operating income attained 09 April 2001  Cerep Reports 2000 Consolidated Results Profitability Attained For The Full Year 07 February 2001  Cerep Announces A Drug Discovery Agreement With Roche 01 February 2001  Cerep Reports 2000 Consolidated Sales: Up 70% - Profitability Reached During The Second Half Of The Year - 11 January 2001  Cerep Announces Four Collaborative Agreements In Combinatorial And Medicinal Chemistry 02 November 2000  Cerep Reports Third Quarter 2000 Consolidated Sales: Up 100% 27 September 2000  Cerep Announces 6 Months Consolidated Financial Results Net Loss Declines 65% Board Of Directors Reinforced 28 August 2000  Cerep Announces Drug Discovery Service Contract with Solvay 23 August 2000  Cerep Reports recent success in its collaboration with Bristol-Myers Squibb 09 August 2000  Cerep Reports Second Quarter 2000 Consolidated Sales: Up 76% 15 May 2000  Cerep Reports First Quarter 2000 Consolidated Sales: up 77 % 19 April 2000  Cerep Reports 1999 Consolidated Results 16 March 2000  Cerep Welcomes President Clinton’s Proposals For The Human Genome 11 February 2000  Cerep Reports Year End and Fourth Quarter Revenues 12 November 1999  Cerep Announces Its Sales For The Third Quarter 1999 14 October 1999  Cerep Announces 6 Months Consolitated Financial Results 27 September 1999  Cerep And Rhône-Poulenc Agro Announce Two Collaborative Agro-chemistry Agreements 24 September 1999  Cerep Joins Phase II Of Combinatorial Chemistry Consortium 11 August 1999  Cerep Reports Second Quarter Revenues Company Launches Two Novel Drug Discovery Tools 21 July 1999  Cerep And Bristol Myers Squibb Announce Strategic Collaborative Agreement 14 June 1999  Cerep And Tibotec Enter HIV Drug Discovery Collaboration 14 May 1999  Cerep Announces Drug Discovery Partnership With Pfizer Company Reports First Quarter Sales 1999 04 May 1999  Cerep Today Announced That It Will Be Implementing Changes To Its Management Structure In Order To Focus On Strengthening Both The Commercial And Operational Responsibilities 15 April 1999  Cerep Reports Fiscal Year End 1998 Results 20 February 1999  Cerep And Sanofi Expand Drug Discovery Collaboration 15 February 1999  Cerep Reports Year End And Fourth Quarter Revenues 29 January 1999  Cerep Appoints Vice President Of Technology Development And Director Of External Operations For Combinatorial Chemistry 25 November 1998  Cerep Signs Strategic Drug Discovery Agreement With ExonHit Therapeutics 13 November 1998  Cerep Reports Third Quarter Revenues 11 November 1998  Cerep Appoints Vice President Of Drug Discovery And Vice President Of Business Development 28 September 1998  Cerep Announces 6 Months Financial Results 11 August 1998  Cerep Reports Second Quarter Revenues 22 June 1998  Cerep Signs Licensing Agreement With Xenometrix Inc. Company profile Cerep worldwide Cerep mission & strategy Key management & Board Analyst coverage Financials Highlights Prospects Key financials Stock News & events Press releases Conferences Shareholders' info Financial calendar Document publicly available Other Financial reports Investor contact Français :: Home :: Site map :: Legal notice :: Credits ::